Novartis will exhibit its latest COVID-19 detection products and solutions at MEDICA 2021

Düsseldorf, Germany, November 3, 2021/PRNewswire/ - Nanjing Novazin Biotechnology Co.

Novartis will showcase its full range of new coronary pneumonia products and solutions at the exhibition, focusing on launching its latest virus detection products SARS-CoV-2 & FLU A/B RT-QPCR and SARS-CoV-2 & FLU A/ B Ag Rapid Test, both of these products can simultaneously detect new coronary pneumonia, A and B influenza and other three viruses, realizing more efficient and comprehensive virus detection

Since the outbreak of the epidemic, Novartis has continuously launched a series of new coronary pneumonia detection reagents and related equipment for nucleic acid detection, rapid antigen, rapid antibody and rapid neutralizing antibody detection

Novartis will exhibit more COVID-19 diagnostic products and solutions, including:

——Nucleic acid detection reagent

——SARS-CoV-2 Ag Rapid Test

——SARS-CoV-2 Ag Home Test

——SARS-CoV-2 & FLU A/B Ag Rapid Test

——Neutralizing antibody detection kit

--and many more

The global in vitro diagnostic market has grown significantly, and the demand for comprehensive, accurate, and customized diagnostic solutions is increasing

In addition to point-of-care (POCT) diagnostic equipment, as a leading upstream supplier of medical raw materials, Novartis also strives to provide customers with the best medical raw material products and services

In order to further benefit billions of customers worldwide, Novartis is accelerating its footprint expansion in overseas markets, focusing on developing the European market by establishing a wide range of local businesses

Introduction

Founded in 2012, Novartis is one of the few domestic R&D and innovative enterprises that have both independent and controllable upstream technology development capabilities and terminal product production capabilities